CLINICAL TRIALS PROFILE FOR NAMENDA XR
✉ Email this page to a colleague
All Clinical Trials for NAMENDA XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00120874 ↗ | Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training | Completed | Fisher Center for Alzheimer's Research Foundation | Phase 4 | 2006-08-01 | The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease. |
| NCT00120874 ↗ | Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training | Completed | Forest Laboratories | Phase 4 | 2006-08-01 | The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease. |
| NCT00120874 ↗ | Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training | Completed | New York University School of Medicine | Phase 4 | 2006-08-01 | The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease. |
| NCT00120874 ↗ | Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training | Completed | NYU Langone Health | Phase 4 | 2006-08-01 | The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease. |
| NCT00181298 ↗ | Memantine in Systemic Lupus Erythematosus | Completed | Forest Laboratories | N/A | 2006-03-01 | Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor. |
| NCT00181298 ↗ | Memantine in Systemic Lupus Erythematosus | Completed | Johns Hopkins University | N/A | 2006-03-01 | Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NAMENDA XR
Condition Name
Clinical Trial Locations for NAMENDA XR
Trials by Country
Clinical Trial Progress for NAMENDA XR
Clinical Trial Phase
Clinical Trial Sponsors for NAMENDA XR
Sponsor Name
